AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer
09 déc. 2024 07h03 HE
|
AiViva Biopharma
AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma...
AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
23 août 2024 07h00 HE
|
AiViva Biopharma
Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully...
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
11 déc. 2023 08h00 HE
|
AiViva Biopharma
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced...
AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors
18 sept. 2023 06h00 HE
|
AiViva Biopharma
COSTA MESA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...
AiViva Biopharma 任命 Jung-Chin (Rongjin) Lin 為董事會成員
29 août 2023 19h00 HE
|
AiViva Biopharma
加利福尼亞州科斯塔梅薩, Aug. 29, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc. 是一家臨床階段生物技術公司，致力於開發創新療法以應對潛力巨大的醫療需求，其於今日宣布任命 Jung-Chin (Rongjin) Lin 先生為其董事會成員。Jung-Chin (Rongjin) Lin 先生是 Center Laboratories,...
AiViva Biopharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors
29 août 2023 19h00 HE
|
AiViva Biopharma
COSTA MESA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
22 mai 2023 06h00 HE
|
AiViva Biopharma
Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a...
AiViva Biopharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer
02 oct. 2020 08h00 HE
|
AiViva Biopharma
NEWPORT BEACH, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun dosing patients diagnosed with superficial or...
AiViva Biopharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
25 juin 2020 08h00 HE
|
AiViva Biopharma
AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds Reduction in fibrosis was observed from single AIV001 treatment post-wounding NEWPORT BEACH,...